Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/217599
AAV8-mediated <em>SIRT1</em> gene transfer to the liver prevents high carbohydrate diet-induced non-alcoholic fatty liver disease
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease worldwide, and evidence suggests that it promotes insulin resistance and type 2 diabetes. Caloric restriction (CR) is the only available strategy for NAFLD treatment. The protein deacetylase Sirtuin1 (SIRT1), which is activated by CR, increases catabolic metabolism and decreases lipogenesis and inflammation, both involved in the development of NAFLD. Here we show that adeno-associated viral vectors of serotype 8 (AAV8)-mediated liver-specific Sirt1 gene transfer prevents the development of NAFLD induced by a high carbohydrate (HC) diet. Long-term hepatic SIRT1 overexpression led to upregulation of key hepatic genes involved in β-oxidation, prevented HC diet-induced lipid accumulation and reduced liver inflammation. AAV8-Sirt1–treated mice showed improved insulin sensitivity, increased oxidative capacity in skeletal muscle and reduced white adipose tissue inflammation. Moreover, HC feeding induced leptin resistance, which was also attenuated in AAV8-Sirt1–treated mice. Therefore, AAV-mediated gene transfer to overexpress SIRT1 specifically in the liver may represent a new gene therapy strategy to counteract NAFLD and related diseases such as type 2 diabetes
Matèries
Matèries (anglès)
Citació
Citació
VILÀ PRATS, Laia, ELIAS, Ivet, ROCA, Carles, RIBERA SÁNCHEZ, Albert, FERRÉ MASFERRER, Tura, CASELLAS, Alba, LAGE RODRIGUES, Luis ricardo, FRANCKHAUSER, Sylvie, BOSCH I TUBERT, Fàtima. AAV8-mediated <em>SIRT1</em> gene transfer to the liver prevents high carbohydrate diet-induced non-alcoholic fatty liver disease. _Molecular Therapy. Methods & Clinical Development_. 2014. [consulta: 24 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/217599]